Neurogen (NRGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (466)	6/22/2007 12:26:22 PM
From: tuck	Read Replies (1) of 523

>>Gotta look at the burn. The psychological overhang of that shelf creates a sell the news environment for the stock.<< Company had ~$107 million at YE 2006, and has guided for $70 million in burn this year. So, yeah, that shelf would probably be put into use by year end. Should a catalyst move the stock, I would probably sell again, and wait for the financing to buy back in. The only catalyst I know of is data on the insomnia compound for sleep maintenance, due in the 2nd half. I wouldn't expect this to be a huge driver unless it can beat Hypnion's very good data in that metric. Certain trials may start, but I am unaware of any other data expected before year end. Anybody know differently? What have they said about partnering (i.e. any possibility of a deal on the insomnia program or obesity programs?)? TIA & Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next